Kirkeby Cell Therapy APS: Financial statements 2019
CVR: 38650165
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Kirkeby Cell Therapy APS (CVR 38650165) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 189,347 and a net result of DKK 255,569 compared with DKK 71,312 the year before. That is an increase of 58.1% compared with the year before. Equity in the 2019 report amounted to DKK 1,112,116. The solvency ratio was 90.4%.
- Gross Profit
- DKK 189,347
- Profit/Loss
- DKK 255,569
- Equity
- DKK 1,112,116
- Total Assets
- DKK 1,229,709
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Kirkeby Cell Therapy APS has published its annual report for 2018. Gross profit came to DKK 119,793, and the net result was DKK 71,312.
About Kirkeby Cell Therapy APS
Kirkeby Cell Therapy APS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2017. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Kirkeby Cell Therapy IVS and Kirkeby Cell Therapey IVS. The management consists of Agnete Kirkeby. The company is owned by Agnete Kirkeby. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 25,872 and a net result of DKK -19,504 compared with DKK 111,159 the year before. Equity in the 2025 report amounted to DKK 1,541,351.